Sawai Shooting for 12.7% Annual Growth for Upsher-Smith: Exec

Kenzo Sawai, Executive Managing Director, Sawai Pharmaceutical Japanese generic major Sawai Pharmaceutical is aspiring to achieve an annual growth rate of 12.7% through 2021 for Upsher-Smith Laboratories, an US peer it acquired in June, as its home market loses steam...read more